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Some GABAA receptors (GABAARs) are activated by low transmitter levels present in the extracellular
space and generate an uninterrupted conductance referred to as ‘‘tonic.’’ This tonic conductance is
highly sensitive to all factors regulating the amount of GABA surrounding the neurons. Only a few
GABAARs with particular subunit combinations are well suited to mediate the tonic conductance.
These same receptors constitute important and specific targets for various endogenous and exog-
enous neuroactive compounds and possible therapeutic targets.Introduction
Chemical communication within the body occurs at three
different temporal and spatial domains: (1) the endocrine
system relies on the bloodstream to carry messengers rel-
atively slowly but in a spatially unrestricted manner, (2) vol-
ume transmission through the extracellular space is much
faster but can only reach neighboring cells by diffusion of
transmitter over hundreds of microns, and (3) synaptic
transmission, which is the fastest, but requires specialized
structures (synapses) between two communicating cell
partners separated only by 20 nm. In the mammalian
CNS, GABA synapses were long known to generate fast
and precisely timed inhibitory activity in the form of inhib-
itory postsynaptic currents (IPSCs or phasic inhibition)
(Mody et al., 1994; Farrant and Nusser, 2005). But over
the last decade, diffusional inhibitory transmission medi-
ated by GABAARs located outside the synapses and acti-
vated by the GABA levels present in the extracellular
space has triggered a great deal of interest (Mody, 2001;
Semyanov et al., 2004; Farrant and Nusser, 2005; Cavelier
et al., 2005; Semyanov, 2005; Vizi and Mike, 2006; Orser,
2006). This form of inhibition is generally referred to as
tonic inhibition, while the conductance generated by the
GABAARs is known as tonic conductance. Such conduc-
tance has been found in a large variety of principal neu-
rons and interneurons, including those found in the cere-
bellum, cortex, hippocampus, thalamus, and spinal
cord. This review focuses on some new developments
and technical issues related to the tonic inhibition of adult
neurons and attempts to call out for a standardized ap-
proach for its recording and measurement.
Which GABAA Receptors Mediate the Tonic
Conductance?
The GABAARs responsible for mediating a current that is
‘‘always on’’ should fulfill certain criteria. First and fore-
most, the receptor should have a sufficiently high GABAaffinity to be activated by the near micromolar GABA con-
centrations present in the extracellular space (Nyitrai et al.,
2006). This is in sharp contrast to the GABAARs situated at
synapses that need not have a high GABA affinity to react
rapidly to fast rises in cleft GABA concentrations to 1.5–3
mM that decay within a few hundred microseconds (Mozr-
zymas et al., 2003). Establishing the precise affinity for
GABA of the native GABAARs, whether synaptic or not, is
not an easy task. Specific interactions with other neuronal
proteins and cell-specific posttranslational modifications
can make receptors found on the surface of neurons to
function unlike those studied in heterologous expression
systems, where GABA affinity can be easily determined.
The contributions to the phasic and tonic currents of a
multitude of GABAARs with different GABA affinities may
make it even more difficult to determine the role of a recep-
tor with a specific subunit composition. To make things
more complicated, some GABAARs can be tonically active
in the absence of any ligand (McCartney et al., 2006), and
thus their contribution to the tonic current may artificially
increase the apparent GABA affinity of the combined pool
of receptors generating the tonic conductance. A second
important factor to consider in the tonic activation of
GABAARs is desensitization. This is a common property
of ligand-gated ion channels characterized by long pe-
riods of closed (nonconducting) states while the agonist
is still bound to the receptor. Considering the single-chan-
nel conductance to be the same, a fewer number of non-
desensitizing receptors would be needed to generate
a tonic conductance of a given size, but the simultaneous
openings of a much larger number of desensitizing recep-
tors could also sum to produce a tonic current of similar
magnitude. But clearly, receptors with high GABA affinity
and little desensitization would be better suited to mediate
a tonic conductance. Thus far, only four types of hetero-
pentameric GABAAR assemblies containing either the d,
a5, or 3 subunits or receptors containing only ab subunitsNeuron 56, December 6, 2007 ª2007 Elsevier Inc. 763
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tion, the tonic conductance of a variety of central neurons.
Considering the various a, b, and g subunits that can as-
semble with these specific subunits, probably no more
than a dozen GABAAR subunit combinations mediate
the tonic conductance in the brain.
The GABAARs containing d subunits (GABAARd) in com-
bination with either a4 or a6, and b2 or b3 subunits satisfy
both the high affinity and limited desensitization criteria.
Their half-maximal activation by GABA (EC50) is in the
tens of nanomolar range, well within the range of GABA
found in the extracellular space (Saxena and Macdonald,
1994; Wallner et al., 2003). The GABAARds also have a low
degree of desensitization in the continuous presence of
agonist (Haas and Macdonald, 1999; Wohlfarth et al.,
2002; Bianchi and Macdonald, 2003). In addition, these
subunits have two other interesting properties that aid
their function as one of the prime mediators of tonic inhi-
bition throughout the brain. The first is their extra- and
perisynaptic localization. The GABAARds are scattered
over the surface of cerebellar granule cells (Nusser et al.,
1998) at locations far from the synapses (extrasynapti-
cally). In the granule cells of the dentate gyrus, another
area of the brain with high levels of d subunits, the same
receptors are localized somewhat closer to the outside
edges of synapses (perisynaptically); this is an ideal loca-
tion to sense GABA spilled over following vesicular release
from nearby boutons or to be activated by the ambient
levels of GABA present in the extracellular space (Wei
et al., 2003). Their second property is the inefficiency of
coupling GABA binding to channel gating, i.e., GABA is
a low-efficacy agonist at d subunit-containing GABAARs.
It is not intuitively obvious why GABA should be a low-ef-
ficacy agonist at d subunit-containing GABAARs while
their affinity for GABA is very high. But this interesting
property means that the predominant mechanism for en-
hancing the function of these receptors may be through in-
creasing the efficacy of GABA as an agonist instead of in-
creasing their already exceptionally high affinity for GABA.
This property may be critical in mediating the actions of
potent endogenous modulators of GABAAR function,
i.e., 3a-hydroxy ring A-reduced pregnane steroids (neuro-
steroids), the brain-derived metabolites of ovarian and
corticosteroids (Majewska et al., 1986; Belelli and Lam-
bert, 2005). Neurosteroids enhance the efficacy of GABA
at GABAARd (Wohlfarth et al., 2002; Bianchi and Macdon-
ald, 2003). The low efficacy of GABA at these receptors
also means that there might be other compounds that
are more efficacious than GABA itself. The GABA agonist
gaboxadol (4,5,6,7-tetrahydroisoxazolo-[5,4-c]pyridine-
3-ol, or THIP) is such a compound (Brown et al., 2002).
The overall properties of GABAARds make them ideal for
mediating a tonic current activated by GABA circulating
in the extracellular space. Indeed, physiological/pharma-
cological approaches and the use of null mutants have
unequivocally shown that in several cell types of the
mammalian CNS, including the cerebellar granule cells
(Stell et al., 2003), dentate gyrus granule cells (Stell et al.,764 Neuron 56, December 6, 2007 ª2007 Elsevier Inc.2003), thalamic neurons (Cope et al., 2005; Bright et al.,
2007), layer 2/3 pyramidal cells (Drasbek and Jensen,
2006), and interneurons of the dentate molecular layer
(Glykys et al., 2007), these receptors predominate in gen-
erating a tonic conductance.
In addition to the GABAARds, GABAARa5 has also been
shown to be critically involved in mediating tonic currents
in CA1 and CA3 pyramidal cells (Caraiscos et al., 2004;
Glykys and Mody, 2006, 2007; Cheng et al., 2006; Prenosil
et al., 2006) and in cortical layer 5 pyramidal cells (Yamada
et al., 2006). The GABAARa5s also have a high GABA affin-
ity and relatively low desensitization (Burgard et al., 1996;
Caraiscos et al., 2004). Receptors devoid of a third type of
subunit, i.e., only containing a and b subunits that are
highly sensitive to Zn2+, have been shown to contribute
to the tonic current recorded in hippocampal neurons
(Mortensen and Smart, 2006). Moreover, the 3 subunit-
containing GABAARs found on CA3 pyramidal cells may
not even require GABA for ligand-independent openings
that could underlie a tonic current (McCartney et al., 2006).
Many different GABAAR types capable of generating a
tonic conductance may be simultaneously expressed on
the surface of a neuron. However, only some types may
be active during a given condition. As conditions change
around the neurons, for example through alterations of
GABA levels (Scimemi et al., 2005), the presence of mod-
ulators, localization of the GABA source, developmental
alterations, or other factors, different fractions of tonically
active GABAARs may be contributing to the total mea-
sured tonic current. Figure 1 illustrates how the fractional
contribution of various GABAAR assemblies to the total
tonic conductance may obscure some, or nearly all, of the
effects of a d subunit-specific modulator (ethanol) on the
total tonic conductance recorded in three types of hippo-
campal neuron. This situation presents interesting chal-
lenges for developing pharmacological approaches to a
cell- or brain-region-specific modulation of tonic inhibition.
Technical Issues Related to the Recording
and Measurement of Tonic Inhibition
Under the right conditions, a tonic inhibitory conductance
mediated by GABAARs is easy to record in a variety of
preparations. Just what exactly are the ‘‘right’’ conditions?
Most preparations amenable for electrophysiological re-
cordings use nerve cells removed from their natural envi-
ronment—the brain. The existence of a tonic conductance
in cerebellar granule cells recorded in vivo (Chadderton
et al., 2004) proves that the tonically active GABAAR-me-
diated conductance is not an artifact of in vitro prepara-
tions. Nevertheless, the conditions used to record tonic
conductances mediated by GABAARs in vitro are still as
diverse as the investigators performing the recordings.
The amount of GABA present in the extracellular space
of an in vitro preparation mostly depends on the volume in
which GABA is dissolved (the extent of the extracellular
space). This space varies depending on the region of the
brain, the age of the animal from which the tissue was
obtained, and the manner in which the slices are kept for
Neuron
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the level of tissue oxygenation. Hypoxia shrinks the extra-
cellular space (Nicholson and Sykova, 1998), which may
lead to an increased GABA concentration in this com-
partment. In submerged slices (used for visualized
patch-clamp recordings), tissue O2 tension needs to be
increased by enhancing the flow rate of the oxygenated
solution to produce oscillations (Hajos et al., 2004) readily
observed in the brain or in slices maintained in an inter-
face-type chamber. Such increased perfusion rate may
wash away the ambient transmitter, leading to a reduction
or even elimination of the tonic current, particularly in cells
on the surface of the slices.
Other problems are posed by the temperature at which
the recordings are done, by the age of the animals from
which slices are prepared, and the general health of the
tissue. At room temperature, the efficiency of amino acid
transporters is decreased (Asztely et al., 1997; Mitchell
and Silver, 2000). As GABA transporters are critical for
controlling GABA levels in the extracellular space (see be-
low), a diminished GABA uptake at room temperature may
be sufficient to activate the tonic conductance.
Slices used for recordings are mostly prepared from
young or ‘‘juvenile’’ mice or rats (<21 days of age). At
this age, many of the neurotransmitter systems, their re-
ceptors, and second messengers have not yet matured,
thus making difficult a fair comparison with studies carried
out in fully mature (>60 days old) animals. A high frequency
Figure 1. The Cartoon Illustrates the Various Types of GABAA
Receptor Assemblies Known to Be Involved in Generating
Tonic Conductances
The different subunit-containing receptors are denoted by different
colors. According to the relative distribution of these receptors on
the cell surface and the specific conditions leading to their activation,
in any given cell a mixture of receptors may be responsible for gener-
ating a compound tonic conductance. The right panel illustrates this as
a hypothetical graph in three different types of hippocampal neurons:
a dentate gyrus granule cell, a CA1 pyramidal cell, and a dentate gyrus
molecular layer interneuron. Depending on the ratios of specific recep-
tors contributing to the tonic current, a modulator that is specific only
to certain subunits (e.g., ethanol for the d subunit-containing receptors)
(Mody et al., 2007), may have its effects obscured by the contribution
to the tonic current of receptors insensitive to the compound.of spontaneous firing of GABAergic interneurons or a large
number of damaged glial cells or neurons could also con-
tribute to raising ambient GABA levels. The amount of
GABA present in the extracellular space may be standard-
ized by blocking the GABA-degrading enzyme GABA-
transaminase with vigabatrin, by adding GABA uptake
blockers, or GABA itself (see below) to the extracellular so-
lution. Unfortunately, none of the approaches used in vitro
will fully mimic the conditions found in the intact brain.
Compared to the conditions of recording, there is con-
siderably more agreement in the literature on the method
of measurement of the tonic GABA-generated conduc-
tance. One usually measures the difference current in
the absence and the presence of a GABAAR blocker. In
practice, the mean holding current during a given segment
of arbitrary length is measured in the presence of the an-
tagonist and is compared to the mean current recorded
during several segments of equal length recorded prior
to the antagonist administration (Nusser and Mody,
2002). We have recently refined this method to separately
measure tonic and phasic inhibitions during consecutive
arbitrary epochs (Glykys and Mody, 2007). This method al-
lows the continuous monitoring of tonic and phasic con-
ductances and any potential correlation between the
two. When comparing tonic conductances between differ-
ent cell types, it is a good practice to express it as a nor-
malized value (in pS/pF) that accounts for the surface of
the cell that is electrically controlled.
Very low amplitude tonic currents (a few pA) make it im-
practical to measure absolute changes. In such instances
it may appear useful to measure the root-mean-squared
(RMS) value of the current or the change in the RMS noise
(which is equivalent to measuring a change in the variance)
of the current.
The RMS for a number of n successive digitized data
























(also referred to as ‘‘RMS noise’’) becomes
RMS2 = I2m + s
2
Because the openings of the active channels should
sum to generate the current, a larger current should be
characterized by a larger variance. Yet, specific alterations
in channel properties (see Figure S1 available online),Neuron 56, December 6, 2007 ª2007 Elsevier Inc. 765
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(and thusRMS), but not ins2. Caution should be exercised
when judging changes in baseline currents simply based
on the change in RMS noise alone.
The type of GABAAR blocker and its concentration used
to reveal the tonic conductance should also be carefully
chosen. As GABAARs mediating tonic and phasic conduc-
tances most likely have different GABA affinities (Stell and
Mody, 2002), care must be taken to use antagonists at
sufficiently large concentrations to block both types of
GABAAR. Moreover, for the channels that are tonically
active in the absence of GABA (e.g., the GABAAR3), bicu-
culline may be the only drug of choice, as gabazine does
not block these receptors (McCartney et al., 2006). Bicu-
culline, however, by blocking SK-type K+ channels (Kha-
waled et al., 1999), could confound the measurement of
tonic inhibition. Picrotoxin may affect GABAARs specific
only to certain cell types (Semyanov et al., 2003), as well
as Cl channels not operated by GABAARs.
The Tonic Conductance and the Composition
of the Artificial Cerebrospinal Fluid
The CSF and the extracellular fluid of the brain are not just
simple mixtures of salts in solution that are commonly
used to prepare the artificial CSF (aCSF) for in vitro record-
ings. Additions of ascorbic acid or Na-pyruvate to reduce
oxidative stress and to enhance slice viability are com-
mon, but real CSF ingredients such as amino acids and
other neuroactive compounds are invariably left out. In or-
der for ‘‘tonic’’ inhibition to be always on, the continuous
presence of the agonist (in this case GABA) is required
around the cells. Neurons in brain slices do release
GABA, as it is clear from the frequent GABAergic inhibitory
postsynaptic events that can be recorded without any
stimulation. But these events are generated by vesicular
GABA release into the synaptic cleft, where on the post-
synaptic side there are dozens of receptors eager to
bind the excess transmitter. In contrast, the receptors re-
sponsible for the tonic inhibition are mostly found just out-
side (perisynaptically) or far away from synapses (extrasy-
naptically). The open environment of a brain slice perfused
with aCSF at rates of 1–10 ml/min may not withhold suffi-
cient levels of transmitter to activate receptors at a consid-
erable distance from the release sites. In some cases, not
even this ‘‘harsh’’ washing can prevent GABA from reach-
ing extrasynaptic sites. This happens at specialized syn-
apses where glial ensheathing or glomerular structure
might prevent rapid diffusion, as in cerebellar granule cells
and dLGN thalamic relay neurons where tonic GABAergic
inhibition can be recorded without the need of adding
GABA to the aCSF. In other parts of the brain, tonic cur-
rents can be observed under some conditions without
supplementing the aCSF with GABA. Tonic GABAA con-
ductance recorded under such conditions could be con-
sidered ‘‘physiological,’’ but it is debatable whether the
sources of GABA are ‘‘physiological’’ in such slice prepa-
rations. It is equally disputable whether it is ‘‘unphysiolog-
ical’’ to provide isolated and perfused brain tissue with766 Neuron 56, December 6, 2007 ª2007 Elsevier Inc.natural ingredients of the brain’s extracellular space by in-
cluding them in the aCSF. Today, nobody in their right
mind would consider Ca to be an ‘‘artificial’’ additive of
the aCSF (or Ringer’s solution). Yet, Sydney Ringer him-
self didn’t think of including Ca in his famous solution until
the day a solution prepared not from distilled water, but
from water supplied by the New River Water Co., contain-
ing 38.3 ppm Ca (almost 1 mM), sustained the beating of
a frog’s heart maintained in vitro (Miller, 2004).
Supplementing the aCSF with amino acids and other
neurotransmitters is complicated by the discrepancies in
the measurements of amino acid concentrations present
in the CSF and extracellular space (Nyitrai et al., 2006).
Furthermore, different brain areas have different extracel-
lular levels of amino acids, and local activity-dependent
changes can also offset the measurements. A meeting
of microdialysis experts and slice physiologists may be a
good way to start developing a consensus on this topic.
The Role of GABA Uptake and the Source of GABA
The concentration of a diffusing substance released from
a source into the extracellular space will depend on the ex-
tracellular space volume fraction, tortuosity, and the pres-
ence of buffering systems (Nicholson and Sykova, 1998).
The tortuosity has both a geometric and a viscous compo-
nent (Rusakov and Kullmann, 1998) that will slow the diffu-
sion of neurotransmitter, in this case GABA in the extracel-
lular space. The buffering systems consist of transporters,
receptors, and other GABA binding sites. The most effec-
tive component of these buffering systems is the GABA
transporter that not only passively binds GABA but also
actively removes it from the extracellular space. The
GABA transporters are high-affinity Na+/Cl-dependent
membrane translocators of GABA (Chen et al., 2004).
There are three transporters specialized in GABA trans-
port (SLC6A1 [GAT-1], SLC6A13 [GAT-2], and SLC6A11
[GAT-3, homologous to mouse mGAT-4]) with specific re-
gional and cellular distribution in the brain (Conti et al.,
2004). GAT-1, the most prevalent GABA transporter, has
a relatively high density on the surface of the neurons.
There are around 1000 mGAT-1 molecules/mm2 in the
neighborhood of GABA synapses (Chiu et al., 2002). Con-
sidering the few thousand GABA molecules in the synaptic
cleft corresponding to a GABA concentration of 1.5–3 mM
(Mozrzymas et al., 2003) and a maximum of hundreds of
GABAARs, the uptake molecules should bind the largest
fraction of the released GABA. The binding and subse-
quent removal of GABA makes the uptake system the
most effective regulator of GABA concentrations in the ex-
tracellular space and thus it should be considered one of
the most important regulators of the tonic conductance.
Indeed, tonic inhibition is exquisitely sensitive to the
amount of GABA uptake (Nusser and Mody, 2002; Semya-
nov et al., 2003). Accordingly, GAT-1-deficient mice have
much higher levels of tonic conductance (Jensen et al.,
2003), which may be the cause of their phenotype of
tremor, ataxia, and nervousness (Chiu et al., 2005). In ad-
dition to GAT-1, GAT2/3 may be involved in soaking up
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naptic receptors (Keros and Hablitz, 2005). As under cer-
tain conditions the GABA uptake system may also func-
tion in reverse, it can become a source of GABA rather
than a sink (Richerson and Wu, 2003). It has been sug-
gested that the very source of GABA for the large tonic
current seen in some recorded neurons is the release
through the reversed transport from the recorded cells
themselves (Richerson and Wu, 2003). In contrast, the
several-fold increases in tonic currents recorded in GAT-
1-deficient mice (Jensen et al., 2003; Chiu et al., 2005)
tend to argue against the role of a reversed GABA trans-
port through GAT-1 as the source for GABA. Neverthe-
less, GABA release through reversal of uptake may con-
stitute an important source of extracellular GABA,
particularly under specific experimental conditions when
cells are overly depolarized or when the Na+ concentration
inside the cells is altered. The uptake of amino acids in the
brain is highly temperature sensitive (Asztely et al., 1997;
Mitchell and Silver, 2000), with a Q10 for the mGAT-4 as
high as 4.3 (Karakossian et al., 2005), and many other
additional factors, such as posttranslational modifica-
tions, regional differences, tissue oxygenation, and devel-
opmental stage, can also influence GABA transporter ac-
tivity. Therefore, the contribution of the GABA transporter
to the tonic conductance should be determined for each
preparation to clarify possible discrepancies between
data obtained in different labs. Since uptake systems ac-
tive in a brain slice can reduce GABA levels even when
GABA is included in the aCSF (Glykys and Mody, 2006)
and because GABA uptake has the lion’s share of control
over the tonic conductance, the modulation of the uptake
should be addressed before suspecting the modulation of
the receptors responsible for generating the tonic current
(Mody et al., 2007). Eventually it will be necessary to deter-
mine the free GABA concentrations present in slices of
various brain regions, with and without added GABA, at
various depths under the slice surface as well as under
high or low levels of neuronal activity. In the absence of fast
and reliable GABA-sensing devices, the ingenious method
using outside-out patches (Isaacson et al., 1993) contain-
ing GABAARs may be a way to systematically measure
slice GABA levels that could originate fromdiverse sources.
Astrocytic release (Kozlov et al., 2006), reversal of GABA
transporter (Richerson and Wu, 2003), and nonvesicular re-
lease, as well as action potential-mediated release (Attwell
et al., 1993; Brickley et al., 1996; Rossi et al., 2003; Bright
et al., 2007; Glykys and Mody, 2007) have all been pro-
posed to contribute to extracellular GABA in slices. Early
on in development in cerebellar granule cells the tonic cur-
rent depends on the firing of action potentials (Kaneda
et al., 1995; Brickley et al., 1996), but in adult granule cells
this source of GABA is replaced by action potential-inde-
pendent mechanisms (Wall and Usowicz, 1997; Rossi
et al., 2003). But, since the inhibitory inputs onto cerebellar
granule cells form a unique synaptic structure, the glial en-
sheathed glomerulus, transmitter release, diffusion, and
overspill may be unique to this highly specialized synapse.The rest of the brain has less specialized GABA synap-
ses than those on cerebellar granule cells. Generally, there
seems to be a correlation between the magnitudes of
tonic and phasic inhibition, indicating that there might be
a common source of GABA for the activation of the two
types of conductances. In mouse spinal cord dorsal horn
lamina II neurons, the phasic and tonic currents are corre-
lated (Ataka and Gu, 2006), but this is not the case in the
magnocellular vasopressin and oxytocin secretory neu-
rons, where the local glial GABA transporter GAT-3 con-
trols the level of tonic conductance (Park et al., 2006). At
the synapses of dLGN thalamic relay neurons, tonic inhibi-
tion depends on the global level of inhibitory activity and
vesicular release (Bright et al., 2007). We recently estab-
lished high temporal correlations between the two types
of inhibitory activity under conditions of both increases
and decreases of vesicular GABA release (Glykys and
Mody, 2007). If vesicular GABA release is proven to be
the source of GABA responsible for both types of inhibi-
tion, the analogy between tonic inhibition and the sound
of a distant orchestra playing at the synapses (Soltesz
and Nusser, 2001) will prove to be correct. If, however,
most of the GABA in the extracellular space originates
from sources other than synaptic vesicles, then tonic inhi-
bition might be playing a different tune than the synaptic
symphony. In the intact brain, it is very likely that various
physiological and pathological conditions can shift the
balance between the many possible sources and sinks
of GABA controlling tonic inhibition.
Functional and Therapeutical Perspectives
on Tonic GABAA Inhibition
During ontogeny and in the absence of synaptic contacts,
diffusional neurotransmission is the norm, and much has
been written about the role of GABA in the development
and maturation of neurons born both in the develop-
ing and the adult CNS (Owens and Kriegstein, 2002;
Ge et al., 2007). As the topic of this review is the tonic
GABAAR-mediated conductance found in fully developed
neurons, the role of the tonic conductance during devel-
opment and maturation will not be discussed here. It is
not difficult to see how a steady conductance of a consid-
erable magnitude can affect neuronal excitability. When
compared to the charge carried by the phasically active
(synaptic) channels, the tonically active receptors invari-
ably come out on top by a margin of 3:1 to 5:1 (Mody
and Pearce, 2004; Cavelier et al., 2005). This is not to
say that the phasic conductance does not have a role in
controlling excitability, but its actions have to be consid-
ered in a highly timed fashion depending on the input re-
ceived by the interneurons as well as by their targets. In
contrast, the presence of an uninterrupted GABA conduc-
tance will control the overall gain of the neuronal input-
output (Mitchell and Silver, 2003; Chadderton et al.,
2004; Semyanov et al., 2004; Cavelier et al., 2005).
Uninterrupted as the tonic conductance may be, this
property should not be taken to mean that the conduc-
tance remains constant in its magnitude over time.Neuron 56, December 6, 2007 ª2007 Elsevier Inc. 767
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concentrations of GABA surrounding the cells or in the
number or properties of the GABAARs responsible for the
conductance can have profound effects of neuronal excit-
ability. We are just beginning to explore the functional con-
sequences of the changes in d subunit-containing GA-
BAARs during the ovarian cycle (Maguire et al., 2005;
Lovick, 2006), their altered expression in certain models
of epilepsies (Peng et al., 2004; Zhang et al., 2007), or of
their variants as the genetic basis for certain human epilep-
sies (Mulley et al., 2005). The high sensitivity of the tonically
active GABAARs to stress-related neurosteroids (Stell
et al., 2003) and to sobriety-impairing concentrations of
ethanol (Mody et al., 2007) will open new opportunities
for understanding the effects of stress and ethanol on the
brain. There might be potential clinical use of gaboxadol,
a compound with high specificity and efficacy for GA-
BAARd, as a novel hypnotic that enhances slow wave sleep
(Wafford and Ebert, 2006). Gaboxadol has also been pro-
posed for the treatment of premenstrual dysphoric disor-
der (Maguire et al., 2005), and these may be but the first
steps in uncovering the clinical usefulness of a new class
of compounds enhancing the function of tonically active
GABAARs.
The critical role of the tonically active a5 subunit-con-
taining GABAARs in learning and memory and cognition
has been highlighted by numerous pharmacological and
mouse knockout studies (Caraiscos et al., 2004; Dawson
et al., 2006). L655,708 is an imidazo[1,5-a]benzodiazepine
that is a selective and high-affinity (Kd 2.5 nM) ligand for
GABAARa5 (Quirk et al., 1996). Together with other related
a5 subunit-selective inverse agonists such as RY80 (Liu
et al., 1996) or a5IA [i.e., 3-(5-methylisoxazol-3-yl)-6-
[(1-methyl-1,2,3-triazol-4-yl)methyloxy]-1,2,4-triazolo[3,4-
a]phthalazine], these compounds have been suggested
for use against cognitive dysfunction based on their spe-
cific actions of enhancing the excitability of CA1/3 hippo-
campal neurons by presumably reducing the tonic inhibi-
tion mediated by GABAARa5 (Atack et al., 2006; Dawson
et al., 2006). In addition, the gene encoding the a5 subunit
(GABRA5) figures prominently among the several candi-
date genes for schizophrenia, and more recently among
those linked to bipolar disorder and depression (Kato,
2007). The disproportionately large charge carried by ton-
ically active GABAARs compared to that mediated by the
phasic conductance makes tonic inhibition the preferred
site of action of several sedative-hypnotic drugs (Orser,
2006). Interestingly, the amnestic effects of etomidate,
but not its sedative-hypnotic actions, can be attributed to
the enhancement of the tonic conductance mediated by
GABAARa5 of hippocampal pyramidal cells (Cheng et al.,
2006).
Another potential intervention for controlling the amount
of the tonic GABAAR-mediated conductance is regulating
the levels of extracellular GABA through altering the func-
tion of GABA transporters. Reducing the function of GAT-
1 by tiagabine is already an effective therapy for epilepsy
(Gether et al., 2006) and may prove to be a promising tar-768 Neuron 56, December 6, 2007 ª2007 Elsevier Inc.get for anxiety disorders (Schwartz and Nihalani, 2006). It
is important to note, however, that increasing extracellular
GABA levels either by inhibiting GABA uptake (e.g., by tia-
gabine) or by reducing the degradation of GABA by inhib-
iting GABA-transaminase (e.g., by vigabatrin) will have
a combined effect consisting of an increased tonic con-
ductance mediated by ionotropic GABAARs and an en-
hanced activation of the metabotropic GABABRs. Indeed,
the potential effectiveness of tiagabine in treating cocaine
addiction is most likely due to an effect of GABA on
GABABRs (Sofuoglu and Kosten, 2005). The most serious
side-effect of vigabatrin therapy is visual dysfunction in-
cluding retinal atrophy, but the underlying mechanism is
not well understood, and no link to any specific GABA sys-
tem has been established (Wheless et al., 2007). In con-
trast to the beneficial effect of tiagabine in epilepsy,
some antiepileptic drugs, such as valproate, may actually
decrease the function of GABA transporters (Whitlow
et al., 2003). Interestingly, GAT-1 knockout mice exhibit
a constant and significant increase in the tonic GABAA
conductance, but no sign of an elevated GABABR activa-
tion (Jensen et al., 2003). These mice have motor disor-
ders, including gait abnormality, constant 25–32 Hz
tremor, reduced rotarod performance, and reduced loco-
motor activity in their home cage (Chiu et al., 2005).
In spite of the recent surge of interest in the identity and
function of tonically active GABAARs, there are quite
a number of important unresolved issues surrounding
the tonic GABAA conductance that have yet to be ad-
dressed experimentally. For example, we do not know
how most receptors responsible for this conductance
are kept away from synapses, ensuring their confinement
to extrasynaptic or perisynaptic sites. There are no reports
on the effects of posttranslational modifications of the ton-
ically active receptors. We know little about their turnover
rates or about the regulation of their expression on the cell
surface by endo- or exocytosis. Not much is known about
functional changes in these receptors during development
or aging. Furthermore, although the experimental tech-
niques are in place, we are still in the dark about the pre-
cise GABA affinity and GABA efficacy of these receptors
when found in their natural habitat, i.e., on neurons of
the CNS. Getting the answers to some of these questions
and a continued high level of interest in GABAAR-medi-
ated tonic conductances will lead us onto an exciting sci-
entific journey to unexplored territories where we can
begin elucidating how critical neuroactive compounds af-
fect the brain, thus gaining insights into the mechanisms
of several debilitating neurological and psychiatric
disorders.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/56/5/763/DC1/.
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